1. Poland Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Captor Therapeutics SA

Captor Therapeutics SA

57.90
PLN
-0.70
(-1.19%)
-7.81EPS
485.14MMarket Cap
Dec 02Next Earn
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
0.15
- -
- -
- -
0.97
2.2
2.84
3.4
0.84
0.35
Basic EPS, GAAP
-0.06
-1.36
-2.55
-3.9
-7.89
-8.61
-15.19
-8.25
-7.61
-7.74
Free Cash Flow per Basic Share
0.64
-0.69
1.28
-0.25
-8.14
-5.51
-11.24
-6.84
-6.76
-13.01
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
0.04
1.05
1.31
-0.31
30.09
23.11
14.9
11.73
4.26
10.27
Tangible Book Value per Share
- -
1.03
1.24
-0.41
30
22.92
14.58
11.48
4.05
10.12
Basic Weighted Avg Shares
3
3
3
3
4
4
5
5
6
6
Sales/Revenue/Turnover
- -
- -
- -
- -
4
9
13
16
5
2
Operating Margin (%)
-28.06
-25,812.5
- -
- -
-820.57
-440.75
-553.11
-246.24
-936.33
-2,311.12
Depreciation Expense
1
3
4
7
7
7
5
5
4
4
Net Income, GAAP
- -
-4
-8
-13
-33
-36
-71
-38
-42
-44
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
-37.97
-27,637.5
- -
- -
-817.16
-391.94
-534.69
-242.82
-901.22
-2,207.63
Working Capital
-1
- -
-1
-7
114
88
62
58
19
61
LT Debt
1
7
6
7
3
3
1
3
2
1
Total Equity
- -
3
4
-1
124
96
69
64
23
65
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
- -
-247.38
-215.49
- -
- -
-32.55
-85.28
-57.48
-95.5
-80.62

Capital Structure

PLN

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
2
2
2
LT Borrowings
- -
- -
- -
LT Finance Leases
2
1
1
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
6
6
6
Market Capitalization
397
443
485

Working Capital

PLN

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
34
21
75
Cash, Cash Equivalents & STI
32
18
72
Accounts Receivable, Net
- -
- -
1
Inventories
- -
- -
- -
Total Current Liabilities
15
13
14
Payables & Accruals
- -
- -
- -
ST Debt
2
2
2
Deferred Revenue
- -
- -
- -

Growth Rates

PLN

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
-2,518.33%
-63.58%
Free Cash Flow
- -
827.16%
17.07%
Net Income, GAAP
- -
45.43%
9.29%
Sales/Revenue/Turnover
- -
- -
-70.55%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

PLN

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
5
5
4
3
16
2025
3
2
- -
- -
5
2026
- -
2
- -
- -
- -

Quarterly Earnings Per Share

PLN

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-2.03
-2.14
-2.2
-1.59
-8.25
2025
-1.95
-1.77
-2.08
-1.82
-7.61
2026
-2.05
-1.81
- -
- -
- -

Quarterly Dividends Per Share

PLN

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Michal Jerzy Walczak
Full Time Employees
82
Sector
Health technology
Industry
Pharmaceuticals: major
Address
ul. Dunska 11 Wroclaw DS Poland 54-427
IPO Date
Apr 19, 2021
Website
captortherapeutics.com
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Captor Therapeutics Spolka Akcyjna, a clinical-stage biopharmaceutical company, discovers and develops targeted protein degradation therapeutics using its proprietary Optigrade platform for oncology and autoimmune indications. The company offers bifunctional degraders and molecular glues targeting proteins including GSPT1, NEK7, SALL4 for hepatocellular carcinoma, lung cancer and neuroendocrine tumors; brain-penetrant and systemic NEK7 degraders for neuroinflammation in Parkinson's disease, ALS and multiple sclerosis, as well as autoimmune diseases such as IBD and gout; MCL-1 degraders for hematological malignancies and solid tumors; PKC-theta degraders for autoimmunity, oncology and transplantation; and early-stage projects for new targets and E3 ligases. Captor Therapeutics operates preclinical and clinical programs from laboratories in Wroclaw, Poland, and business development in Basel, Switzerland, targeting patients with high unmet needs in cancer and inflammatory diseases. Founded in 2015 and headquartered in Wroclaw, Poland, the company listed on the Warsaw Stock Exchange in 2022. Recent developments include initiation of a Phase 1 clinical trial for lead candidate CT-01 in hepatocellular carcinoma in May 2025; a strategic research collaboration and option agreement in November 2025 with an undisclosed U.S. pharmaceutical company for NEK7 degraders providing mid-single-digit million USD upfront potential and triple-digit million USD milestones; and a research collaboration agreement with MD Anderson Cancer Center in November 2025.